News

Astra Zeneca ends AZD2820 study
Enlarge image

BusinessSwedenUK

Astra Zeneca ends AZD2820 study

11.09.2012 - Swedish-British pharma Astra Zeneca has stopped the development of one obesity drug but promises to back partner Palatin with the other candidates.

US company Palatin Technologies, Inc. (Cranbury) experienced a setback for one of its developed drugs in June this year when its partner AstraZeneca PLC from Europe paused a Phase I clinical trial after a serious adverse event. Now, the Swedish-British pharma giant decided, after a thorough review, to end the development of this drug completely. However, Palatin also announced that AstraZeneca remains committed to the collaboration programme at large to discover, develop and commercialise compounds that target melanocortin-4 receptors for the treatment of obesity, diabetes and related metabolic syndrome.

The ditched clinical candidate called AZD2820 is a subcutaneously-administered peptide that partially agonises the melanocortin-4 receptor. Phase I clinical trials as a single-agent therapy for the treatment of obesity started in the first half of 2011 after AstraZeneca had selected the drug from the collaborative research programme with Palatin Technologies. The single centre study was expected to enrol 90 subjects with a body mass index between 30 and 35 in a randomised, single-blind, placebo-controlled, Phase I trial in healthy male volunteers. After 11 subjects had completed their dosing regimen, the trial was halted by the Safety Review Committee because it suspected that one subject may have had an allergic reaction following his first dose. The volunteer fully recovered but the review by AstraZeneca said that it cannot be excluded that the adverse reactiom was linked to AZD2820. The company however also stated, that it is unlikely that this event was related to melanocortin receptor activation as a mode of action.

http://www.european-biotechnology-news.com/news/news/2012-03/astra-zeneca-ends-azd2820-study.html

PoliticsFranceUKSweden

24.04.2015 AstraZeneca has boosted its oncology portfolio by signing a US$1.275bn agreement with Innate Pharma. The companies plan to further the development of Innate’s tumour-targeting antibody.

PoliticsEU

22.04.2015 A legislative proposal by the European Commission is set to renationalise market authorisation of genetically modified crops.

FinancingUK

21.04.2015 Ahead of its listing on the London Stock Exchange, Woodford’s Patient Capital Trust has raised a record sum of €1.1bn. The fund met with immense interest by investors.

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DBelgium

14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.

Stock MarketsEUFranceUKNorwaySweden

09.04.2015 The European public markets remain highly attractive for biotech companies. Twice as many companies went public in the first quarter of 2015 than during the same period last year.

FinancingAustriaUKSwitzerlandGermany

08.04.2015 To bring its lead product of a new class of antimicrobials to phase 3 trials, Nabriva Therapeutics has completed a US$120m Series B financing.

Research & DevelopmentNetherlands

07.04.2015 Gene therapy is attracting more and more big pharma companies. Now, Bristol-Myers Squibb has forged a US$1bn collaboration with Dutch uniQure, also picking up a 4.9% share in the company.

Stock MarketsFrance

02.04.2015 Sensorion is the latest French biotech to go public, following a spate of IPOs on Paris Euronext. The biopharma plans for a €12m IPO to finance its pipeline of inner ear disease drugs.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • WILEX4.84 EUR34.82%
  • FORMYCON31.25 EUR11.61%
  • PAION2.76 EUR6.98%

FLOP

  • MEDIGENE12.41 EUR-3.42%
  • SANTHERA96.75 CHF-2.12%
  • MOLOGEN5.01 EUR-1.18%

TOP

  • WILEX4.84 EUR63.5%
  • FORMYCON31.25 EUR35.0%
  • CO.DON3.35 EUR29.8%

FLOP

  • CYTOS1.08 CHF-22.9%
  • BIOTEST78.40 EUR-18.9%
  • THERAMETRICS0.07 CHF-12.5%

TOP

  • SANTHERA96.75 CHF2368.1%
  • CYTOS1.08 CHF671.4%
  • WILEX4.84 EUR469.4%

FLOP

  • MOLOGEN5.01 EUR-55.5%
  • BIOFRONTERA2.40 EUR-26.8%
  • THERAMETRICS0.07 CHF-22.2%

No liability assumed, Date: 27.04.2015